Literature DB >> 12399960

Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol.

N I Noguera1, M Breccia, M Divona, D Diverio, V Costa, S De Santis, G Avvisati, M B Pinazzi, M C Petti, F Mandelli, F Lo Coco.   

Abstract

Alterations in the FLT3 gene, including internal tandem duplications (ITDs) and D835 mutations occur frequently in acute myelogenous leukemia. We investigated the prevalence and clinico-biological correlations of FLT3 ITDs and D835 mutations in 90 patients with acute promyelocytic leukemia (APL) receiving the AIDA protocol. Twenty patients in which both presentation and relapse material was available were analyzed sequentially. Thirty-three patients (37%) harbored the ITD, and seven (7.7%) the D835 mutation in blasts obtained at diagnosis. Presence of ITDs was strongly associated with high WBC count (P = 0.0001), M3 variant (P = 0.0004), and the short (BCR3) PML/RARalpha isoform (P = 0.003). There was no difference in response to induction in the two ITD+ve and ITD-ve groups, while a trend towards inferior outcome was observed for ITD+ve cases when analyzing disease-free survival (DFS) and relapse risk (RR). These differences, however, did not reach statistical significance. Sequential studies showed variable patterns in diagnostic and relapse material, ie ITD (-ve/-ve, +ve/+ve, +ve/-ve, -ve/+ve) and D835 (-ve/-ve, +ve/-ve, -ve/+ve). Our results indicate that FLT3 alterations are associated in APL with more aggressive clinical features and suggest that these lesions may not play a major role in leukemia progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399960     DOI: 10.1038/sj.leu.2402723

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  46 in total

Review 1.  Clinical significance of FLT3 in leukemia.

Authors:  Hitoshi Kiyoi; Masamitsu Yanada; Kazutaka Ozekia
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

2.  FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis.

Authors:  Massimo Breccia; Giuseppina Loglisci; Maria Giovanna Loglisci; Roberto Ricci; Daniela Diverio; Roberto Latagliata; Robin Foà; Francesco Lo-Coco
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

3.  Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.

Authors:  Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; Wolfgang Kern; Tamara Alpermann; Torsten Haferlach
Journal:  Haematologica       Date:  2011-08-22       Impact factor: 9.941

4.  Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900.

Authors:  Hugo F Fernandez; Zhuoxin Sun; Mark R Litzow; Selina M Luger; Elisabeth Paietta; Janis Racevskis; Ross L Levine; Jay P Patel; Omar Abdel-Wahab; Rhett P Ketterling; Gordon W Dewald; John M Bennett; Jacob M Rowe; Hillard M Lazarus; Martin S Tallman
Journal:  Haematologica       Date:  2018-11-22       Impact factor: 9.941

5.  Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.

Authors:  Marlise R Luskin; Ju-Whei Lee; Hugo F Fernandez; Omar Abdel-Wahab; John M Bennett; Rhett P Ketterling; Hillard M Lazarus; Ross L Levine; Mark R Litzow; Elisabeth M Paietta; Jay P Patel; Janis Racevskis; Jacob M Rowe; Martin S Tallman; Zhuoxin Sun; Selina M Luger
Journal:  Blood       Date:  2016-01-11       Impact factor: 22.113

6.  Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.

Authors:  Robert E Gallagher; Barry K Moser; Janis Racevskis; Xavier Poiré; Clara D Bloomfield; Andrew J Carroll; Rhett P Ketterling; Diane Roulston; Esther Schachter-Tokarz; Da-Cheng Zhou; I-Ming L Chen; Richard Harvey; Greg Koval; Dorie A Sher; James H Feusner; Martin S Tallman; Richard A Larson; Bayard L Powell; Frederick R Appelbaum; Elisabeth Paietta; Cheryl L Willman; Wendy Stock
Journal:  Blood       Date:  2012-06-25       Impact factor: 22.113

7.  Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin.

Authors:  Hugo F Fernandez; Zhuoxin Sun; Mark R Litzow; Selina M Luger; Elisabeth M Paietta; Janis Racevskis; Gordon Dewald; Rhett P Ketterling; Jacob M Rowe; Hillard M Lazarus; Martin S Tallman
Journal:  Blood       Date:  2011-03-17       Impact factor: 22.113

8.  Anthracycline dose intensification in acute myeloid leukemia.

Authors:  Hugo F Fernandez; Zhuoxin Sun; Xiaopan Yao; Mark R Litzow; Selina M Luger; Elisabeth M Paietta; Janis Racevskis; Gordon W Dewald; Rhett P Ketterling; John M Bennett; Jacob M Rowe; Hillard M Lazarus; Martin S Tallman
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

9.  Possible involvement of RasGRP4 in leukemogenesis.

Authors:  Naoko Watanabe-Okochi; Toshihiko Oki; Yukiko Komeno; Naoko Kato; Koichiro Yuji; Ryoichi Ono; Yuka Harada; Hironori Harada; Yasuhide Hayashi; Hideaki Nakajima; Tetsuya Nosaka; Jiro Kitaura; Toshio Kitamura
Journal:  Int J Hematol       Date:  2009-04-07       Impact factor: 2.490

10.  PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.

Authors:  L Cicconi; M Divona; C Ciardi; T Ottone; A Ferrantini; S Lavorgna; V Alfonso; F Paoloni; A Piciocchi; G Avvisati; F Ferrara; E Di Bona; F Albano; M Breccia; E Cerqui; M Sborgia; M G Kropp; A Santoro; A Levis; S Sica; S Amadori; M T Voso; F Mandelli; F Lo-Coco
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.